Jeffrey S Berger Selected Research

Morbid Obesity

10/2022	Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.
11/2021	More frequent olive oil intake is associated with reduced platelet activation in obesity.
1/2019	Severe obesity and bariatric surgery alter the platelet mRNA profile.
1/2019	Elevated GlycA in severe obesity is normalized by bariatric surgery.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey S Berger Research Topics

Disease

48	Hemorrhage 10/2022 - 01/2006
41	Myocardial Infarction 01/2022 - 06/2005
35	Peripheral Arterial Disease 05/2022 - 05/2009
25	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 01/2006
24	Stroke (Strokes) 01/2022 - 01/2006
19	Ischemic Stroke 01/2022 - 01/2006
16	Coronary Artery Disease (Coronary Atherosclerosis) 05/2022 - 06/2005
14	Inflammation (Inflammations) 01/2022 - 05/2011
14	COVID-19 01/2022 - 01/2020
14	Ischemia 01/2022 - 08/2013
13	Coronary Disease (Coronary Heart Disease) 10/2021 - 09/2004
12	Thrombosis (Thrombus) 01/2022 - 05/2006
12	Atherosclerosis 01/2021 - 06/2005
11	Diabetes Mellitus 01/2022 - 01/2012
11	Atrial Fibrillation 11/2021 - 08/2016
9	Obesity 10/2022 - 01/2018
8	Venous Thromboembolism 11/2022 - 05/2015
7	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2019
7	Acute Coronary Syndrome 12/2018 - 11/2008
6	Critical Illness (Critically Ill) 01/2022 - 01/2020
5	Hypertension (High Blood Pressure) 01/2022 - 04/2006
5	Unstable Angina 01/2022 - 02/2005
4	Body Weight (Weight, Body) 11/2022 - 01/2019
4	Morbid Obesity 10/2022 - 01/2019
4	Neoplasms (Cancer) 10/2022 - 12/2009
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2020 - 05/2012
4	Hyperglycemia 10/2019 - 05/2014
4	Heart Failure 02/2019 - 09/2016
3	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2019
3	Infections 01/2022 - 03/2009
3	Chronic Renal Insufficiency 12/2021 - 01/2017
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 01/2018
3	Atherosclerotic Plaque (Atheroma) 01/2021 - 01/2019
3	Insulin Resistance 10/2020 - 02/2013
3	Chronic Limb-Threatening Ischemia 01/2020 - 01/2012
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2018 - 01/2008
3	Vascular Diseases (Vascular Disease) 01/2018 - 08/2009
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 01/2008
3	ST Elevation Myocardial Infarction 01/2014 - 01/2008
2	Wounds and Injuries (Trauma) 03/2022 - 10/2021
2	Dementia (Dementias) 01/2022 - 01/2021
2	Transient Ischemic Attack 01/2022 - 01/2018
2	Pulmonary Embolism 01/2022 - 01/2018
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 01/2018
2	Anemia 12/2021 - 03/2016

Drug/Important Bio-Agent (IBA)

28	Clopidogrel (Plavix)FDA Link 05/2022 - 11/2008
24	TicagrelorIBA 01/2022 - 09/2013
22	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2022 - 01/2006
11	RivaroxabanIBA 10/2022 - 01/2017
11	omega-Chloroacetophenone (Mace)IBA 10/2021 - 07/2017
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2008
7	Warfarin (Coumadin)FDA LinkGeneric 10/2022 - 10/2017
7	CholesterolIBA 01/2021 - 04/2012
6	LipidsIBA 01/2022 - 05/2011
6	HDL LipoproteinsIBA 01/2021 - 02/2013
5	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 08/2016
5	RNA (Ribonucleic Acid)IBA 09/2021 - 10/2016
5	Proteins (Proteins, Gene)FDA Link 09/2021 - 06/2013
5	Interleukin-6 (Interleukin 6)IBA 04/2021 - 06/2017
5	C-Reactive ProteinIBA 04/2021 - 04/2008
5	oxidized low density lipoproteinIBA 01/2021 - 04/2012
4	AnticoagulantsIBA 10/2022 - 01/2018
4	P-SelectinIBA 12/2021 - 08/2011
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2021 - 12/2009
4	CytokinesIBA 04/2021 - 06/2017
4	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 04/2012
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 01/2012
4	Glucose (Dextrose)FDA LinkGeneric 10/2018 - 05/2012
3	Adenosine Diphosphate (ADP)IBA 01/2022 - 07/2013
3	Fibrinogen (Factor I)FDA Link 01/2022 - 06/2013
3	Hemoglobins (Hemoglobin)IBA 12/2021 - 03/2016
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
3	Triglycerides (Triacylglycerol)IBA 01/2021 - 04/2012
3	Lipoproteins (Lipoprotein)IBA 10/2020 - 04/2012
3	Vitamin K FDA Link 10/2018 - 01/2017
3	TroponinIBA 08/2017 - 03/2013
2	Oxygen (Dioxygen)IBA 01/2022 - 01/2022
2	fibrin fragment D (D-dimer)IBA 01/2022 - 10/2020
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2021 - 01/2021
2	Indicators and Reagents (Reagents)IBA 04/2021 - 11/2006
2	InterleukinsIBA 04/2021 - 01/2021
2	Interleukin-17 (Interleukin 17)IBA 04/2021 - 01/2021
2	InterferonsIBA 01/2021 - 01/2020

Therapy/Procedure

35	Therapeutics 01/2022 - 06/2005
15	Surgical Amputation (Amputations) 01/2022 - 01/2012
15	Percutaneous Coronary Intervention 01/2019 - 09/2004
8	Secondary Prevention 01/2022 - 01/2008
6	Perioperative Period 10/2019 - 03/2013
5	Stents 01/2020 - 04/2006
5	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 11/2008
4	Length of Stay 03/2022 - 11/2008
4	Critical Care (Surgical Intensive Care) 12/2021 - 01/2020
3	Patient Readmission 01/2022 - 01/2018
3	Artificial Respiration (Mechanical Ventilation) 05/2021 - 01/2020
3	Bariatric Surgery 10/2020 - 01/2019
3	Vascular Surgical Procedures 01/2020 - 01/2018
2	Knee Replacement Arthroplasty (Total Knee Replacement) 03/2022 - 03/2009
2	Conduction Anesthesia (Regional Anesthesia) 03/2022 - 10/2021
2	Polypharmacy 11/2021 - 01/2021
2	Conservative Treatment 01/2021 - 01/2018